Apollomics Inc.

This Annual Report includes forward-looking statements, principally in the sections entitled Item 3.D. “Key Information—Risk Factors,” Item 4. “Information on the Company,” and Item 5. “Operating and Financial Review and Prospects.” In some cases, these forward-looking statements can be identified by words or phrases such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “seek,” “believe,” “estimate,” “predict,” “potential,” “continue,” “contemplate,” “possible” or similar words. Statements regarding our future results of operations and financial position, growth strategy and plans and objectives of management for future operations, including, among others, expansion in new and existing markets, are forward-looking statements.

Our forward-looking statements are mainly based on our current expectations and estimates of future events and trends which affect or may affect our business, operations and industry. Although we believe that these forward-looking statements are based upon reasonable assumptions, they are subject to numerous risks and uncertainties, including without limitation those described under the sections in this Annual Report entitled Item 3.D. “Key Information—Risk Factors” and Item 5. “Operating and Financial Review and Prospects” and elsewhere in this Annual Report.

Our forward-looking statements may be influenced by factors including:

•

Factors relating to our business, operations and financial performance, including, but not limited to:

•

Our ability to achieve successful clinical results;

•

We do not currently have any products approved for commercial sale;

•

Our ability to obtain regulatory approval for our products, and any related restrictions or limitations of any approved products;

•

Our dependence on the success of vebreltinib, our most advanced product candidate;

•

Our ability to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects;

•

Our ability to commercialize product candidates and achieve market acceptance of such product candidates;

•

Our success is dependent on certain drug candidates for which we have licenses from third parties;

•

•

We have incurred significant losses since inception, and expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future;

•

We require substantial additional capital to finance our operations, and if unable to raise such capital when needed or on acceptable terms, we may be forced to delay, reduce, and/or eliminate one or more of our development programs;

•

•

Our ability to maintain the listing of the Apollomics Class A Ordinary Shares, par value $0.01 per share (the “Class A Ordinary Shares”), on Nasdaq;

•

Changes in global, regional or local business, market, financial, political and legal conditions, including the development, effects and enforcement of laws and regulations and the impact of any current or new government regulations in the United States and China affecting our operations and the continued listing of our securities;

•

•

Assumptions regarding interest rates and inflation;

•

•

Litigation, including an ongoing claim by one investment manager for two minority investors in the Company;

•

Our ability to adequately protect our intellectual property rights; and

•

Other matters described in the section entitled Item 3.D. “Key Information—Risk Factors” beginning on page 4.

Many important factors, in addition to the factors described above and in other sections of this Annual Report, could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risks and uncertainties emerge from time to time, and it is not possible for our management to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.

The forward-looking statements contained in this Annual Report speak only as of the date of this Annual Report. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to reflect the occurrence of unanticipated events.